HighTower Advisors LLC reduced its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 20.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 39,333 shares of the biotechnology company's stock after selling 10,327 shares during the quarter. HighTower Advisors LLC's holdings in Sarepta Therapeutics were worth $4,870,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Comerica Bank lifted its stake in Sarepta Therapeutics by 489.4% during the first quarter. Comerica Bank now owns 3,336 shares of the biotechnology company's stock valued at $432,000 after purchasing an additional 2,770 shares during the last quarter. Cetera Investment Advisers raised its position in shares of Sarepta Therapeutics by 27.6% during the first quarter. Cetera Investment Advisers now owns 11,991 shares of the biotechnology company's stock worth $1,552,000 after purchasing an additional 2,590 shares during the period. CWM LLC lifted its holdings in shares of Sarepta Therapeutics by 30.4% during the second quarter. CWM LLC now owns 871 shares of the biotechnology company's stock valued at $138,000 after purchasing an additional 203 shares during the last quarter. ORG Partners LLC acquired a new position in shares of Sarepta Therapeutics in the 2nd quarter valued at $266,000. Finally, Envestnet Portfolio Solutions Inc. purchased a new position in Sarepta Therapeutics in the 2nd quarter worth about $201,000. Institutional investors and hedge funds own 86.68% of the company's stock.
Sarepta Therapeutics Stock Performance
NASDAQ:SRPT traded down $1.31 during midday trading on Wednesday, reaching $125.39. The stock had a trading volume of 364,569 shares, compared to its average volume of 1,227,883. The stock has a market capitalization of $11.98 billion, a P/E ratio of 100.31 and a beta of 0.77. Sarepta Therapeutics, Inc. has a 1-year low of $86.23 and a 1-year high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The firm's fifty day simple moving average is $122.94 and its 200-day simple moving average is $131.35.
Insider Buying and Selling at Sarepta Therapeutics
In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of the firm's stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now directly owns 5,880 shares in the company, valued at $738,234. This trade represents a 21.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 7.70% of the company's stock.
Analyst Ratings Changes
SRPT has been the topic of several analyst reports. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. Piper Sandler reduced their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a report on Wednesday, November 27th. Raymond James reiterated an "outperform" rating and set a $150.00 price target on shares of Sarepta Therapeutics in a report on Thursday, October 10th. HC Wainwright reduced their price objective on Sarepta Therapeutics from $80.00 to $75.00 and set a "sell" rating for the company in a research note on Tuesday, December 3rd. Finally, Royal Bank of Canada restated an "outperform" rating and set a $182.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Sarepta Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $175.55.
Get Our Latest Research Report on Sarepta Therapeutics
About Sarepta Therapeutics
(
Free Report)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Read More
Before you consider Sarepta Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.
While Sarepta Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
